KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Construction in Progress (2016 - 2017)

Regeneron Pharmaceuticals (REGN) has 5 years of Construction in Progress data on record, last reported at $408.9 million in Q4 2017.

  • For Q4 2017, Construction in Progress rose 28.2% year-over-year to $408.9 million; the TTM value through Dec 2017 reached $408.9 million, up 28.2%, while the annual FY2017 figure was $408.9 million, 28.2% up from the prior year.
  • Construction in Progress reached $408.9 million in Q4 2017 per REGN's latest filing, up from $318.9 million in the prior quarter.
  • Across five years, Construction in Progress topped out at $579.8 million in Q4 2015 and bottomed at $142.4 million in Q4 2013.
  • Average Construction in Progress over 5 years is $384.4 million, with a median of $408.9 million recorded in 2017.
  • Peak YoY movement for Construction in Progress: skyrocketed 231.69% in 2014, then plummeted 45.0% in 2016.
  • A 5-year view of Construction in Progress shows it stood at $142.4 million in 2013, then surged by 231.69% to $472.2 million in 2014, then grew by 22.79% to $579.8 million in 2015, then tumbled by 45.0% to $318.9 million in 2016, then increased by 28.2% to $408.9 million in 2017.
  • Per Business Quant database, its latest 3 readings for Construction in Progress were $408.9 million in Q4 2017, $318.9 million in Q4 2016, and $579.8 million in Q4 2015.